预约演示

Merck’s Lynparza-Keytruda combo sputters in 2nd lung cancer trial. Will an ADC pairing work instead?

2024-03-21

交易

临床3期抗体药物偶联物临床结果免疫疗法

Besides the two failed trials in metastatic non-small cell lung cancer, Merck is also testing adding Lynparza to Keytruda in stage 3 tumors.

Merck’s attempt to use Lynparza tmetastatic non-small cell lung canceralMerckl lung cancer has come uLynparzawithKeytrudad pistage 3 tumorsilure.

Merckcing the chemotherLynparzatrexed witKeytrudaza dmetastatic non-small cell lung cancerwly diagnosed metastatic nonsquamous NSCLC didn’t improve patients’ life expectancy, nor was the approach able to significantly delay progression or death, Merck said Thursday.

The R&D setback came from tpemetrexed KEYLYLynparzarial. The experimental regimen uses Keytruda in combimetastatic nonsquamous NSCLCoublet as induction treatment, followed by Keytruda plus Lynparza, and then Lynparza alone until progression. Patients in the control group received pemetrexed instead of Lynparza.

The Keytruda-Lynparza pair’s latest flop in nonsquamous NSCLC followed a negative readoKeytrudathe KEYLYNK-008 study in squamous tumors. Before that, the PD-1/PARP inhibitor dKeytrudad to bLynparzanti-androgeLynparzay in previously treated metastatic castration-resistant prostate pemetrexed Lynparza

In NKeytrudaeLynparzamous histology of tumornonsquamous NSCLCcult situation for Lynparza to make a difference. After all, Keytruda and chemo already set aPD-1/PARP inhibitor PD-1/PARPicacy bar, duowing a 51% reduction in the risk of death versus chemo alone.metastatic castration-resistant prostate cancer

TheNSCLCstatic setting aside, Merck is tumorsesting adding Lynparza to Keytruda Lynparza 3 NSCLC. The goal of the KEYLYNK-Keytrudal is actually to use Lynparza and Keytruda to beat Merck’s partner on Lynparza, AstraZeneca.

Chemoradiation therapy followeMerckAZ’s Imfinzi is a standaLynparzare iKeytruda3, ustage 3 NSCLCSCLC. With KEYLYNK-012, Merck is trying to show that coLynparza use KeytrudaradiationMerckKeytruda, follLynparzaKeAstraZeneca or without Lynparza, is superior to AZ’s Imfinzi maintenance regimen.

Given the several recent trial flops, KEImfinzi12 now looks like an uncerstage 3, unresectable NSCLCeytruda-Lynparza disMerckntments in the metastatic setting, AZ in November found that Keytrudant administratKeytrudamfinzi and chemorLynparzaapy missed the mark whImfinziared with the traditional post-chemoradiation Imfinzi regimen in stage 3 NSCLC, according to the phase 3 PACIFIC-2 trial. Not only did the concurrent regimen fail to improve progression-free survival, but it also showed an increased rate of infection.

Still, Merck remains committed to exploring Keytruda-based combinations in lung cancer, Gregory LubKeytruda-Lynparzaglobal clinical development at Merck Research Laboratories, said in a statement Thursday.Imfinzi Imfinzi stage 3 NSCLC infection

MeanwhiMerckntibody-drug conjugates have emeKeytrudapromising combo pairs wlung cancer-1 cancer immunotherapies. ADCs’ tumor-targeted delivery of cMerck Research Laboratoriesl candidates to replace conventional systemic chemotherapy with lower toxicity and hopefully better efficacy.

In metastatic NSCLC, Merck recently launched a phase 3 trial evaluating the combinatPD-1ocancerruda and its investigatitumorTROP2-directed ADC, MK-2870, against Keytruda alone in PD-L1-high NSCLC. A separate phase 3 study is pitting MK-2870 against chemo in previously treated nonsquamous NSCLC with EGFR or other genomic alterations. Merck in-licensed the TROP2 candidate from China’s Kelun Biotech.